BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Emerald BioStructures Appoints Johan Pontin as Chairman and CEO


12/1/2011 8:22:31 AM

BAINBRIDGE ISLAND, WA. December 1 , 2011. Emerald BioStructures today announced the appointment of Johan Pontin as its Chairman and Chief Executive Officer. He succeeds Lance Stewart, Ph.D., MBA, Emerald’s co-founder, who will now serve as Chair of the Company’s Advisory Board. Mr. Pontin has served as Emerald BioStructure’s Executive Chairman since November 2009, in which he has been responsible for leading the Company’s business strategy, and has over 15 years of broad international experience in strategic planning, venture and private equity investments, and corporate and business development.

“Working together with Lance, our joint leadership over the last two years has led Emerald to significantly expand its commercial business by providing first-class customer service. As a result, we have more than doubled revenues and tripled our customer base,” said Mr. Pontin. “I look forward to expanding my involvement in the company as we continue to improve and broaden our service offerings to better serve our customers.” Mr. Pontin previously served as Founding and Managing Partner of Pod Venture Partners, an international closely held private equity firm. He also previously served as Group Manager of Corporate Finance and Mergers and Acquisitions at ASSA ABLOY AB and as a management consultant in the Financial Advisory Services group at Coopers & Lybrand LLC. Mr. Pontin has a Bachelor’s degree from Carroll School of Management at Boston College and served as a PT Boat Commander in the Royal Swedish Navy.

Dr. Stewart co-founded Emerald in 1998 and led the growth of Emerald as a business unit within two publicly traded companies (MCLS and DCGN) and the successful spin out from deCODE genetics in November 2009. During his tenure, Dr. Stewart oversaw Emerald’s research that supported the discovery of eight investigational new drug molecules for clients’ projects. In addition to his ongoing advisory role, Dr. Stewart will continue to serve on behalf of Emerald as the Co-principal Investigator for the Seattle Structural Genomics Center for Infectious Disease (SSGCID), a five-year NIAID-funded collaboration that is solving approximately 500 protein crystal structures of novel infectious disease targets.

Dr. Stewart said: “It has been a tremendous privilege to watch our talented team provide highly enabling structural insights to support our clients’ drug discovery projects. Emerald has proven itself to be a technology leader in structural proteomics, from the creation of our innovative Fragments of Life lead discovery platform to the development of numerous automation solutions for gene-to-structure research. I look forward to contributing to the company as a close advisor.”

About Emerald BioStructures

Emerald BioStructures is an integrated gene-to-structure contract research organization that provides collaborative drug discovery services to pharmaceutical companies, biotechnology companies, academic institutions, and government facilities. The company operates a high-throughput platform leveraged for fragment-based lead discovery, structure-based drug design, and elucidation of antibody-antigen structures. Emerald’s work provides a solid foundation for the discovery of highly selective, efficacious drugs. www.emeraldbiostructures.com

Contacts:

For Emerald BioStructures:

Johan Pontin

(206) 780-8900

For Media:

Jennifer Conrad

MacDougall Biomedical Communications

(781) 235-3060



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES